X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs GSK PHARMA - Comparison Results

LUPIN    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN GSK PHARMA LUPIN/
GSK PHARMA
 
P/E (TTM) x 39.7 53.8 73.8% View Chart
P/BV x 2.4 10.7 22.9% View Chart
Dividend Yield % 0.7 2.7 25.1%  

Financials

 LUPIN   GSK PHARMA
EQUITY SHARE DATA
    LUPIN
Mar-18
GSK PHARMA
Mar-18
LUPIN/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,4652,760 53.1%   
Low Rs7272,040 35.6%   
Sales per share (Unadj.) Rs349.6339.0 103.1%  
Earnings per share (Unadj.) Rs5.641.4 13.4%  
Cash flow per share (Unadj.) Rs29.645.9 64.4%  
Dividends per share (Unadj.) Rs5.0035.00 14.3%  
Dividend yield (eoy) %0.51.5 31.3%  
Book value per share (Unadj.) Rs300.3242.9 123.6%  
Shares outstanding (eoy) m452.0884.70 533.7%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.17.1 44.3%   
Avg P/E ratio x197.257.9 340.3%  
P/CF ratio (eoy) x37.152.3 70.9%  
Price / Book Value ratio x3.69.9 36.9%  
Dividend payout %90.084.5 106.5%   
Avg Mkt Cap Rs m495,502203,280 243.8%   
No. of employees `00017.0NA-   
Total wages/salary Rs m28,6475,234 547.3%   
Avg. sales/employee Rs Th9,273.6NM-  
Avg. wages/employee Rs Th1,681.0NM-  
Avg. net profit/employee Rs Th147.4NM-  
INCOME DATA
Net Sales Rs m158,04228,715 550.4%  
Other income Rs m1,504545 275.7%   
Total revenues Rs m159,54529,260 545.3%   
Gross profit Rs m31,4755,059 622.2%  
Depreciation Rs m10,859380 2,857.6%   
Interest Rs m2,0442 102,175.0%   
Profit before tax Rs m20,0765,222 384.5%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644178 -8,226.7%   
Tax Rs m2,8851,892 152.5%   
Profit after tax Rs m2,5133,508 71.6%  
Gross profit margin %19.917.6 113.0%  
Effective tax rate %14.436.2 39.7%   
Net profit margin %1.612.2 13.0%  
BALANCE SHEET DATA
Current assets Rs m122,09521,815 559.7%   
Current liabilities Rs m50,95615,999 318.5%   
Net working cap to sales %45.020.3 222.2%  
Current ratio x2.41.4 175.7%  
Inventory Days Days8564 133.0%  
Debtors Days Days12019 641.7%  
Net fixed assets Rs m129,87612,475 1,041.1%   
Share capital Rs m904847 106.8%   
"Free" reserves Rs m134,86619,726 683.7%   
Net worth Rs m135,77120,573 659.9%   
Long term debt Rs m64,2456 1,070,750.0%   
Total assets Rs m263,05439,475 666.4%  
Interest coverage x10.82,612.0 0.4%   
Debt to equity ratio x0.50 162,250.5%  
Sales to assets ratio x0.60.7 82.6%   
Return on assets %1.78.9 19.5%  
Return on equity %1.917.1 10.9%  
Return on capital %3.726.2 14.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,141564 9,422.2%   
Fx outflow Rs m19,3357,429 260.3%   
Net fx Rs m33,807-6,865 -492.4%   
CASH FLOW
From Operations Rs m17,5124,728 370.4%  
From Investments Rs m-14,073-1,042 1,350.7%  
From Financial Activity Rs m-14,921-3,066 486.6%  
Net Cashflow Rs m-11,482620 -1,852.8%  

Share Holding

Indian Promoters % 46.6 0.0 -  
Foreign collaborators % 0.2 50.7 0.4%  
Indian inst/Mut Fund % 11.3 10.2 110.8%  
FIIs % 31.9 23.8 134.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 15.4 65.6%  
Shareholders   98,259 102,036 96.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   SUVEN LIFESCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  FDC LTD.  SHASUN PHARMA  

Compare LUPIN With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Realty and Energy Stocks Gain(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.4% while the Hang Seng is up 0.3%.

Related Views on News

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

LUPIN LTD Announces Quarterly Results (2QFY19); Net Profit Down 31.1% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, LUPIN LTD has posted a net profit of Rs 3 bn (down 31.1% YoY). Sales on the other hand came in at Rs 40 bn (up 53.1% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


Mar 26, 2019 12:13 PM

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS